Best Infectious Diseases Companies in Spain
The 35 best Infectious Diseases companies in Spain in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: DeepUll.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in Spain
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DeepUll Developer of diagnostic technology for rapid identification of sepsis-causing pathogens | $35M | 16 mo ago | Series C | 26 | 2020 | Rafel Gibert Co-Founder | — | — |
| 2 | STAT-Dx Point of care system for syndromic testing of respiratory & gastrointestinal pathogens | $34M | 123 mo ago | Acquired | 30 | 2010 | Jordi Carrera Founder & CEO | — | — |
| 3 | SOM Biotech Developer of platform for screening compounds to treat rare diseases | $29M | 33 mo ago | Series B | 15 | 2009 | Raul Insa Founder & CEO | 117 patents Pharmaceutical compounds and formulations for treating dystrophinopathies, movement disorders, and PKU | — |
| 4 | ABAC Therapeutics Early stage biopharma developing precision drugs for MDR bacterial infections | $20M | 44 mo ago | Acquired | 8 | 2014 | Domingo Gargallo-Viola Co-Founder & CSO | 31 patents Novel small‑molecule antibiotics for Gram‑positive bacterial infections (Staph, Strep). | — |
| 5 | Vaxdyn Prophylactic vaccines against multidrug resistant bacterial infections | $14M | 24 mo ago | Series A | 8 | 2011 | — | 20 patents LPS-deficient Acinetobacter baumannii multivalent vaccine formulation and delivery | — |
| 6 | Aelix Therapeutics Developer of therapies for treating HIV | $13M | 80 mo ago | Series A | 10 | 2015 | Christian Brander Co-Founder | 25 patents TLR7 agonist adjuvants and multiepitope T‑cell immunogens for HIV vaccine development | — |
| 7 | Laminar Pharma Developer of melipathy based drugs | $12M | 26 mo ago | Series A | 30 | 2006 | — | — | — |
| 8 | Telum Therapeutics Provider of the drug for treating multi-drug resistance bacterial infection | $5M | 57 mo ago | Series A | 17 | 2019 | Rubén Díez CFO & Co-Founder - BoD member | 6 patents Recombinant lysin enzymes for treating gram‑negative bacterial infections | — |
| 9 | Affirma Biotech Developer of drugs against multi-drug resistant bacteria | $2M | 31 mo ago | Seed | 3 | 2020 | Maribel Berges Chief Executive Officer | 6 patents PD‑L1 immune checkpoint inhibitor biologics for cancer immunotherapy | — |
| 10 | SOMAprobes Provider of diagnostic kits for sensitive diagnosis of various diseases | $2M | 53 mo ago | Funding Raised | 10 | 2014 | Miguel Mulet Co-Founder | 10 patents Rapid point‑of‑care lateral‑flow diagnostics for sepsis, pathogens, and coronavirus detection. | — |
| 11 | Green Vac One Health Biotechnology Developer of vaccines for the treatment of brucellosis | $2M | 54 mo ago | Funding Raised | 8 | 2014 | Ignacio Grillo Co-Founder & CEO | — | — |
| 12 | Archivel Farma Therapeutic and Prophylactic vaccines for latent TB infection | $1M | 103 mo ago | Funding Raised | 20 | 2005 | Jose Martinez Founder | 100 patents Liposomal drug delivery systems for cancer, tuberculosis treatment, and related immunotherapies | — |
| 13 | VLPbio Developer of virus like particles as immunotherapies for cancer and infectious diseases | $998K | 88 mo ago | Seed | 10 | 2011 | — | — | — |
| 14 | Biotica Develops techniques for the microbiological detection. | $779K | 123 mo ago | Deadpooled | — | 2005 | Guillermo Rodriguez Co-Founder | — | — |
| 15 | RemAb Therapeutics Discovering and developing first line therapy for preventing nosocomial infections at ICUs | $112K | 87 mo ago | Funding Raised | 8 | 2018 | Rafael Mañez Co-Founder | 14 patents Synthetic carbohydrate antigen mimetics and glycoconjugates for immunotherapy and diagnostics | — |
Top 12 Infectious Diseases companies in Spain
#1
Series C · Barcelona, Catalonia · founded 2020 · 26 employees$35.5Mraised▾
Developer of diagnostic technology for rapid identification of sepsis-causing pathogens. The company focuses on empowering hospitals with technology to identify pathogens and antibiotic resistance markers directly from blood. The goal is to provide reportable results in about one hour, addressing the critical need for faster diagnosis. The company's technology aims to improve patient outcomes through early and effective treatment.
#2
Series A · Seville, Andalusia · founded 2011 · 8 employees$13.6Mraised▾
Vaxdyn, a spin-off of the University HospitalVirgen del Rocío is focussed on developing vaccines and mAbs against infections caused by multiresistant bacteria. Its lead compound VXD-001 is a preventive vaccine currently in the late preclinical phase for the treatment of A.baumannii infection. It is also developing a prophylactic vaccine which is in discovery phase against P.aeruginosa based on recombinant protein antigens. Additionally, it is developing VXD-003, an mAb in discovery phase for the treatment of A.baumannii infections.
- Sep 2024Grant (prize money)$2.8M
- Sep 2024Series A$13.3M
- Mar 2021Seed$357.3K
- Jul 2020Grant (prize money)—
#3
Series A · Palma, Balearic Islands · founded 2006 · 30 employees$12Mraised▾
Developer of melipathy based drugs. The company provides various products such as LAM561 anticancer drug acting through cell membrane modification, LAM226 Omega-3 lipid derivative which specifically targets neuronal membranes for Alzheimer’s, LAM204 polyunsaturated fatty acid to replace steroid anti-inflammatory treatments and LAM30171 fatty acid derivative as a potential treatment for cancer and metabolic disorders.
- Jul 2024Series A$6.3M
- Oct 2023Series A$8.4M
- Nov 2022Grant (prize money)$280.5K
- Apr 2021Grant (prize money)$189.4K
#4
Series B · Barcelona, Catalonia · founded 2009 · 15 employees$28.5Mraised▾
SOM Biotech is developing therapies for rare diseases. The company has developed a proprietary ligand-based in-silico platform for virtual compound screening. The company has developed a drug pipeline that includes SOM0226 for the treatment of TTR amyloidosis (phase II) and SOM3355 for the treatment of Huntington's disease (phase II). The other products in the pipeline include compounds for the treatments for cystic fibrosis, glioblastoma, and Alzheimer's disease.
- Dec 2023Series B$18.5M
- Mar 2019Series A$7.9M
- Jan 2017Seed$2.1M
#5
Acquired · Barcelona, Catalonia · founded 2014 · 8 employees$19.8Mraised▾
ABAC Therapeutics is early stage biopharma developing precision drugs for MDR bacterial infections. It is developing drugs for the precision treatment of MDR Gram-negative infections. The drug development is based on their proprietary drug discovery platform PasNas which is a scalable and multiplex platform capable of effectively unveiling pathogen-specific antibacterial properties of molecules. Its anti-Gram-negative programs include small molecules for A.baumannii in lead optimization stage and for E.coli, K.pneumoniae, and P.aeruginosa in initial stages. The mechanism of action of the drugs has not been revealed as on Aug.2017. The company has raised €16 million Series A funding for development of drug for MDR bacterial infections in Feb 2018.
- Jan 2023Grant (prize money)$271.2K
- Mar 2021Grant (prize money)$302.1K
- Feb 2018Series A$19.8M
#6
Seed · Barcelona, Catalonia · founded 2020 · 3 employees$2.5Mraised▾
Developer of drugs against multi-drug resistant bacteria. The company is developing drugs against several bacteria which have resistance to different drugs such as Acinetobacter baumannii, Enterobacteriace, and Pseudomonas aeruginosa have carbapenem-resistant, and many others.
- Feb 2024Seed$1.9M
- Sep 2022Seed$600.8K
#7
Acquired · Barcelona, Catalonia · founded 2010 · 30 employees$34.3Mraised▾
STAT Dx is developing molecular diagnostic systems for syndromic testing of various pathogens including bacteria & viruses. The company has developed proprietary technologies, DiagCORE Cartridge & DiagCore Analyser. DiagCORE Cartridge contains all reagents necessary for qPCR procedure including for breaking of cell material, nucleic acid purification, amplification, and hybridization. The cartridge is then analyzed by using DiagCore Analyser. The company has developed two test panels for respiratory & gastrointestinal pathogens.
- 2016Series A$34.3M
#8
Series A · Barcelona, Catalonia · founded 2015 · 10 employees$12.6Mraised▾
Aelix Therapeutics develops therapies for HIV. It is a spinout from Barcelona's HIVACAT Research Center. The company plans to use polynucleotide sequences from T-cells derived from a cohort of HIV patients with naturally low viral loads. These sequence(s) will then be converted into DNA and delivered as a vaccine using a modified Ankara virus (MVA) as a vector. The vaccine has completed a Phase 1 trial.
- Jan 2020Grant (prize money)$600.2K
- Jul 2017Grant (prize money)$57.3K
- Jan 2016Series A$12.6M
#9
Series A · Noain, Navarre · founded 2019 · 17 employees$4.6Mraised▾
Provider of the drug for treating multi-drug resistance bacterial infection. The company's proprietary product includes extraction of antibacterial agents using lytic phage enzymes i.e natural lytic enzymes (NLEs) and chimeric lytic enzymes (CLEs) from soil environments and the identification of bacteriophages (lytic and lysogenic) which can damage the bacterial populations. The company drug pipeline includes P001, TT206, P002, P003, GN, and GP enzybiotics for treating gram-negative bacterial infections by Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
- Dec 2021Series A$4.6M
#10
Funding Raised · Noain, Navarre · founded 2014 · 8 employees$1.7Mraised▾
Developer of vaccines for the treatment of brucellosis. The company develops a vaccine that is viable for use against Brucella melitensis in mammals, which infect humans which are transmitted from cattle and sheep.
- Feb 2022Grant (prize money)$56.3K
- Mar 2020Grant (prize money)$1.6M
- May 2019Grant (prize money)$55.7K
- Dec 2018Grant (prize money)$56.6K
#11
Funding Raised · Gipuzkoa, Basque Country · founded 2014 · 10 employees$1.8Mraised▾
Provider of diagnostic kits for sensitive diagnosis of various diseases. The company leverages nucleases as diagnostic markers in the design of devices for in vitro diagnostics to detect various diseases such as sepsis, coronavirus, and cancer.
- Mar 2022Grant (prize money)$55.7K
- Aug 2020Grant (prize money)$1.7M
#12
Seed · Boecillo, Castile and Leon · founded 2011 · 10 employees$998.4Kraised▾
VLPbio is a developer of virus-like particles as immunotherapies for cancer and infectious diseases. The technology is based on patented and proprietary antigen-display nano-platform based on Virus-Like Particles. This technology allows researchers to incorporate pathology-associated antigens into VLPs generating chimeric nanoparticles (Ch-VLPs). The pipelined products are PRRSVax for Porcine Reproductive & Respiratory Syndrome, and Circovirus. For Humans, they are working on CerviVax, an immunotherapeutic vaccine for the treatment of HPV-16/HPV-18 (Human Papilloma Virus) infections.
- May 2019Grant (prize money)$2.3M
- Sep 2018Grant (prize money)$225K
- Feb 2018Seed$998.4K
- Jul 2017Grant (prize money)$95.2K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Diagnostics is moving in Spain
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,258 Spain-affiliated papers.
- Ministry of Health175
- Centro de Investigación Biomédica en Red de Cáncer128
- Instituto de Salud Carlos III58
- Universitat de Barcelona49
- Barcelona Institute for Global Health47
- Liquid biopsy11→50
- Biopsy1→15
- Point-of-care testing5→15
- Biomarker5→14
- Lung cancer1→10
- Liquid biopsy24→135
- Biopsy4→46
- Point-of-care testing16→54
- Biomarker7→43
- Internal medicine10→45
- Liquid biopsy10→40
- Intensive care medicine2→13
- Biomarker3→13
- Point-of-care testing30→40
- Oncology2→12
Where diagnostics is researched across Spain
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.